Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT07114419




Registration number
NCT07114419
Ethics application status
Date submitted
6/07/2025
Date registered
11/08/2025
Date last updated
11/08/2025

Titles & IDs
Public title
The Efficacy and Safety of Efsubaglutide Alfa in Overweight/Obesity(SPARKLE)
Scientific title
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Efsubaglutide Alfa Injection in Subjects With Overweight or Obesity
Secondary ID [1] 0 0
YN012-II-W204-AU
Secondary ID [2] 0 0
YN012-II-W204-AU
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Obesity and Overweight 0 0
Condition category
Condition code
Diet and Nutrition 0 0 0 0
Obesity
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Efsubaglutide Alfa 20 mg QW
Treatment: Drugs - Efsubaglutide Alfa 40 mg QW
Treatment: Drugs - Efsubaglutide Alfa 40 mg Q2W
Treatment: Drugs - Efsubaglutide Alfa 80 mg QW
Treatment: Drugs - Efsubaglutide Alfa 80 mg Q4W
Other interventions - Placebo

Experimental: Efsubaglutide 20 mg Quaque Week (QW) - The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg ? 5 mg ? 10 mg ? 20 mg, reaching the target dose of 20 mg, the total treatment last for 22weeks.

Experimental: Efsubaglutide 40 mg QW - The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg ? 5 mg ? 10 mg ? 20 ? 40mg, reaching the target dose of 40 mg, the total treatment last for 22weeks.

Experimental: Efsubaglutide Alfa 40 mg Q2W - The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg ? 5 mg ? 10 mg ? 20 ? 40mg,when reaching to target dose of 40 mg, administered the drug every 2weeks. the total treatment last for 22weeks.

Experimental: Efsubaglutide Alfa 80 mg QW - The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg ? 5 mg ? 10 mg ? 20 ? 40mg? 80mg, reaching the target dose of 80 mg, the total treatment last for 22weeks.

Experimental: Efsubaglutide Alfa 80 mg Q4W - The drug is administered once weekly, starting with a titration dose of 1 mg. The dose is up-titrated every 2 weeks in the sequence of 1 mg ? 5 mg ? 10 mg ? 20 ? 40mg? 80mg,when reaching to target dose of 80 mg, administered the drug every 4weeks. the total treatment last for 22weeks.


Treatment: Drugs: Efsubaglutide Alfa 20 mg QW
Efsubaglutide Alfa 20 mg QW

Treatment: Drugs: Efsubaglutide Alfa 40 mg QW
Efsubaglutide Alfa 40 mg QW

Treatment: Drugs: Efsubaglutide Alfa 40 mg Q2W
Efsubaglutide Alfa 40 mg Q2W

Treatment: Drugs: Efsubaglutide Alfa 80 mg QW
Efsubaglutide Alfa 80 mg QW

Treatment: Drugs: Efsubaglutide Alfa 80 mg Q4W
Efsubaglutide Alfa 80 mg Q4W

Other interventions: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percentage change (%) of body weight from baseline after subcutaneous administration of YN-011 for 22 weeks
Timepoint [1] 0 0
22 weeks
Secondary outcome [1] 0 0
Proportion of subjects with body weight loss = 5%, = 10%, and = 15% from baseline after subcutaneous
Timepoint [1] 0 0
22 weeks
Secondary outcome [2] 0 0
Absolute change from baseline in body weight (Kg) after subcutaneous administration for 22 weeks
Timepoint [2] 0 0
22 weeks
Secondary outcome [3] 0 0
Changes from baseline in BMI after subcutaneous administration for 22 weeks
Timepoint [3] 0 0
22 weeks
Secondary outcome [4] 0 0
Changes from baseline in waist to hip circumference ratio after subcutaneous administration for 22 weeks
Timepoint [4] 0 0
22 weeks
Secondary outcome [5] 0 0
Changes from baseline in waist to height ratio after subcutaneous administration of YN-011 for 22 weeks
Timepoint [5] 0 0
22 weeks
Secondary outcome [6] 0 0
Changes from baseline in systolic and diastolic blood pressure after subcutaneous administration for 22 weeks
Timepoint [6] 0 0
22 weeks
Secondary outcome [7] 0 0
Changes from baseline in blood lipids (including TC, TG, LDL-C, and high-density lipoprotein cholesterol [HDL-C]) after subcutaneous administration for 22 weeks, percentage change from baseline, and ratio to baseline
Timepoint [7] 0 0
22 weeks
Secondary outcome [8] 0 0
Changes from baseline in glycated hemoglobin (HbA1c) after administration subcutaneous for 22 weeks
Timepoint [8] 0 0
22 weeks
Secondary outcome [9] 0 0
Changes from baseline in fasting plasma glucose(FPG) after subcutaneous administration of YN-011 for 22 weeks;
Timepoint [9] 0 0
22 weeks
Secondary outcome [10] 0 0
Changes from baseline in fasting insulin after subcutaneous administration of YN-011 for 22 weeks;
Timepoint [10] 0 0
22 weeks
Secondary outcome [11] 0 0
Changes from baseline in blood uric acid after subcutaneous administration for 22 weeks, percentage change from baseline, and ratio to baseline
Timepoint [11] 0 0
22 weeks
Secondary outcome [12] 0 0
Safety assessment will be conducted throught the study by Incidence of adverse events (AEs) and serious adverse events (SAEs);
Timepoint [12] 0 0
22 weeks
Secondary outcome [13] 0 0
Safety assessment will be conducted throught the study by Mental health status via Patient Health Questionnaire-9 (PHQ-9)
Timepoint [13] 0 0
26 weeks
Secondary outcome [14] 0 0
Safety assessment will be conducted throught the study by Mental health status via Columbia Suicide Severity Rating Scale (C-SSRS)
Timepoint [14] 0 0
26 weeks
Secondary outcome [15] 0 0
Maximum plasma concentration (Cmax) of YN-011 via subcutaneous administration through the study
Timepoint [15] 0 0
22 weeks
Secondary outcome [16] 0 0
Timepoint of maximum plasma concentration (Tmax) of YN-011 via subcutaneous administration
Timepoint [16] 0 0
22 weeks
Secondary outcome [17] 0 0
Area under the concentration-time curve from the time zero to last measurable concentration (AUC0-t) of YN-011 via subcutaneous administration
Timepoint [17] 0 0
22 weeks
Secondary outcome [18] 0 0
Elimination half-life (t1/2) of YN-011 via subcutaneous administration
Timepoint [18] 0 0
22 weeks
Secondary outcome [19] 0 0
Apparent clearance (CL/F) of YN-011 via subcutaneous administration
Timepoint [19] 0 0
22 weeks
Secondary outcome [20] 0 0
Apparent volume of distribution (Vz/F) of YN-011 via subcutaneous administration
Timepoint [20] 0 0
22 weeks
Secondary outcome [21] 0 0
Trough concentration (Ctrough) of YN-011 via subcutaneous administration
Timepoint [21] 0 0
22 weeks
Secondary outcome [22] 0 0
Incidence of anti-drug antibody (ADA) against YN-011 in serum before and after subcutaneous administration
Timepoint [22] 0 0
22 weeks
Secondary outcome [23] 0 0
Incidence of neutralizing antibody (NAb) against YN-011 in serum before and after subcutaneous administration
Timepoint [23] 0 0
22 weeks
Secondary outcome [24] 0 0
Changes from baseline in Dual Energy X-ray Absorptiometry [DEXA] data report (DEXA data inculding total fat mass, muscle mass, regional visceral fat mass and total lean body mass) after subcutaneous administration of YN-011
Timepoint [24] 0 0
22 weeks

Eligibility
Key inclusion criteria
1. Willing to comply with protocol required visit schedule and visit requirements and provide written informed consent form (ICF);
2. Male or female subjects, aged 18 to 75 years (both inclusive) at the time of signing the ICF;
3. Obese: BMI = 30.0 kg/m2, with or without comorbidities; Or overweight: 27.0 kg/m2 = BMI < 30.0 kg/m2, with at least one of the following weight-related comorbidities: pre-diabetes, hypertension, dyslipidemia, fatty liver, osteoarthritis, or obesity-induced obstructive sleep apnea syndrome (If the subject has only fatty liver as a comorbidity, imaging results within the 3 months prior to screening are required for fatty liver);
4. A self-reported change in body weight less than 5.0% controlled with diet and exercise within 3 months before screening;
5. Women of childbearing potential (WOCBP) and fertile males with WOCBP partners must use highly effective contraception methods throughout the study (from the signing of ICF to 3 months after the last dose of investigational medicinal products).
Minimum age
18 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Obesity caused by endocrine disease or monogenic mutation, including but not limited to hypothalamic obesity, pituitary obesity, hypothyroidism-related obesity, Cushing's syndrome, insulinoma, acromegaly or hypogonadism;
2. Known or suspected allergy to the investigational medicinal product, its components or drugs of the same class;
3. Previously diagnosed diabetes mellitus (including type 1 diabetes mellitus, type 2 diabetes mellitus, diabetes mellitus due to pancreatic damage, or other types of diabetes mellitus [except gestational diabetes mellitus]);
4. History of severe gastrointestinal disease (e.g., active ulcers), or gastrointestinal surgery (except for appendectomy, cholecystectomy, or other gastrointestinal endoscopic surgeries deemed by the investigator to have no significant impact on gastrointestinal motility), or clinically significant gastric emptying abnormalities (e.g., pyloric obstruction, gastroparesis), or long-term use of drugs with direct effects on gastrointestinal motility within 6 months before screening, or those who were not suitable for participating in this study at the investigator's discretion;
5. History of significant cardiovascular or cerebrovascular disease within 6 months before screening, including but not limited to:1) Myocardial infarction, coronary angioplasty or bypass grafting, heart valve disease or heart valve repair, clinically significant arrhythmias requiring treatment, angina, transient ischemic attack, cerebrovascular accident or others; 2)Congestive heart failure classified as Grade III or IV by the New York Heart Association (NYHA) (refer to Appendix 3);
6. History of acute or chronic pancreatitis, symptomatic gallbladder disease (subjects who have undergone cholecystectomy and have stable condition post-surgery are excluded), or pancreatic injury and other factors that may lead to high risk of pancreatitis;
7. Presence of hyperthyroidism; or hypothyroidism that has not been controlled with a stable medication dose (defined as a stable dose for 3 months or longer);
8. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2);
9. Subjects who have experienced two or more hypoglycemic events within 6 months prior to screening, defined as blood glucose < 2.8 mmol/L (50.4 mg/dl) or blood glucose not reaching < 2.8 mmol/L (50.4 mg/dl) but with significant hypoglycemia symptoms (manifested by sympathetic arousal [e.g., palpitations, anxiety, sweating, dizziness, shaking of the hands, feeling of hunger, etc.] and CNS symptoms [e.g., altered mentation, cognitive disturbances, seizures and coma]);
10. History of an active or untreated malignancy or are in remission from a clinically significant malignancy (other than basal- or squamous-cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years; or there is a potential malignancy during screening;
11. History of severe infection or severe trauma within 3 months prior to screening, or undergoing major surgery or not fully recovering from surgery, and the investigator determines that the participant is unsuitable for this study;
12. History of significant active or unstable major depressive disorder or other severe psychiatric disorder (for example, schizophrenia, bipolar disorder, or other serious mood or anxiety disorder) within 2 years prior to screening;
13. Previous suicidal tendency or suicidal behavior;
14. Suicidal ideation corresponding to type 4 or 5 on the C-SSRS at screening;
15. PHQ-9 questionnaire = 15 points at screening;
16. Known active infections, e.g., bacterial, fungal and viral infections, including: 1)Human immunodeficiency virus (HIV) infection: defined as HIV antibody positive; 2)Syphilis infection: defined as treponema pallidum antibody (TP-Ab) positive; 3)Active hepatitis B virus (HBV): defined as hepatitis B surface antigen (HBsAg) positive and HBV-deoxyribonucleic acid (DNA) = lab-specific upper limit of normal (ULN) (for those with positive result on HBsAg, HBV DNA test will be performed and those with positive HBV DNA results will be excluded); 4)Active hepatitis C virus (HCV): defined as HCV antibody (HCV-Ab) positive and HCV-ribonucleic acid (RNA) positive, if HCV-Ab positive and HCV RNA negative can be considered as eligible at the discretion of the Investigator;
17. Any of the laboratory test results at screening meet the following criteria (if there is a clear reason for re-test, the re-test can be performed once during the screening period, and the investigator should record the reason for re-test): 1)HbA1c = 6.5% or fasting blood glucose = 7.0 mmol/L (126 mg/dL) (fasting blood glucose will be tested at the local laboratory at the time of screening, plasma or serum glucose is acceptable); 2)Thyroid stimulating hormone (TSH) > 6.0 mIU/L or < 0.4 mIU/L; 3)ALT or AST = 3.0×ULN or total bilirubin (TBIL) = 2× ULN; 4)Fasting TG > 5.65 mmol/L (500 mg/dl); 5)Blood amylase or lipase > 2.0×ULN; 6)Calcitonin = 50 ng/L(pg/mL); 7)Estimated glomerular filtration rate (eGFR) = 30 mL/min/1.73m2, calculated by the CKD-EPI formula (refer to Appendix 4); 8)International normalized ratio (INR) > ULN;
18. Abnormal 12-lead ECG: second- or third-degree atrioventricular block, long QT syndrome or QTcF > 450 ms (males) or > 470 ms (females) (refer to Appendix 5), left bundle branch block, Wolff-Parkinson-White syndrome, or other clinically significant abnormalities that require treatment;
19. Uncontrolled hypertension, defined as systolic blood pressure = 160 mmHg and/or diastolic blood pressure = 100 mmHg;
20. Use of any of the following medications or treatments within 3 months prior to screening: 1)Weight loss drugs, such as semaglutide, sibutramine hydrochloride, orlistat, phentermine, phenylpropanolamine, chlorpheniramine, phentermine, bupropion, lorcaserin, phentermine/topiramate mixture, naltrexone/bupropion mixture, etc.; 2)Chinese herbal medicine, health products, meal replacements affecting body weight; 3)Glucose-lowering drugs, such as metformin, SGLT2 inhibitors, GLP-1R agonists, thiazolidinediones (TZDs), etc; 4)Drugs that may affect body weight, including systemic steroids (Consecutively for 7 or more days), tricyclic antidepressants, psychiatric drugs or sedative drugs (such as imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, valproic acid derivatives, lithium salts);
21. Previous bariatric surgery; acupuncture/cupping for weight loss, liposuction, and abdominal liposuction within 1 year prior to screening; or plan to undergo corresponding treatment during the study period;
22. Subjects who have participated in other clinical studies and received investigational drug therapy, vaccines or medical device intervention within 3 months before screening;
23. Blood donation or blood loss = 400 mL within 3 months before screening, or those who have received blood transfusion;
24. Inability to be venipunctured and/or tolerate venous access;
25. Alcohol consumption of > 21 units per week for males and > 14 units per week for females within the 6 months before screening (1 unit=360 mL of beer or 45 mL of spirits with an alcohol content of = 40% or 150 mL of wine);
26. Have a history or suspected abuse of drug, and the investigator determines that the subject is unsuitable for this study;
27. Have history of use of marijuana within 3 months before screening and unwillingness to abstain from marijuana use during the study;
28. Pregnant or lactating women;
29. Other conditions deemed unsuitable for participation in this study according to the judgment of the investigator..

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Not yet recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
1/08/2025
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/08/2026
Actual
Sample size
Target
200
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Canopy Clinical Northern Beaches - Brookvale
Recruitment hospital [2] 0 0
Canopy Clinical Sutherland Shire - Miranda
Recruitment hospital [3] 0 0
Canopy Clinical Altona North - North Altona
Recruitment hospital [4] 0 0
Fusion Clinical Research - Norwood
Recruitment hospital [5] 0 0
Canopy Clinical Wollongong - Wollongong
Recruitment postcode(s) [1] 0 0
- Brookvale
Recruitment postcode(s) [2] 0 0
- Miranda
Recruitment postcode(s) [3] 0 0
- North Altona
Recruitment postcode(s) [4] 0 0
- Norwood
Recruitment postcode(s) [5] 0 0
- Wollongong

Funding & Sponsors
Primary sponsor type
Other
Name
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Karen Kaluhin
Address 0 0
Canopy Clinical Sutherland Shire
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
QINGHUA WANG
Address 0 0
Country 0 0
Phone 0 0
862168788225
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results not provided in https://clinicaltrials.gov/study/NCT07114419